Stocktoria
GILEAD SCIENCES, INC. GILD
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1992-01-22
GILEAD SCIENCES, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 34.0% | 5.8% | 28.0% | 26.9% | 36.3% |
| Net margin | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% |
| FCF margin | 32.1% | 35.8% | 27.4% | 30.6% | 39.6% |
| Return on assets | 14.4% | 0.8% | 9.1% | 7.3% | 9.2% |
| Return on equity | 37.5% | 2.5% | 24.8% | 21.6% | 29.5% |
| Debt / equity | 1.10× | 1.38× | 1.09× | 1.19× | 1.27× |
| Current ratio | 1.55 | 1.60 | 1.43 | 1.29 | 1.27 |
| Revenue growth | 2.4% | 6.0% | -0.6% | -0.1% | 10.6% |
Source: SEC EDGAR filings · CIK 0000882095 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.